<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00848458</url>
  </required_header>
  <id_info>
    <org_study_id>AAI</org_study_id>
    <secondary_id>Eudra-CT Number:2008-003792-52</secondary_id>
    <nct_id>NCT00848458</nct_id>
  </id_info>
  <brief_title>Azelaic Acid Iontophoresis Versus Topical Azelaic Acid Cream in the Treatment of Melasma</brief_title>
  <acronym>AAI</acronym>
  <official_title>Azelaic Acid Iontophoresis Versus Topical Azelaic Acid Cream in the Treatment of Melasma - An Open Randomized, Controlled, Prospective, Single Blinded Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective, randomized, controlled, single-blinded investigation is to
      study the efficacy, tolerability and safety of azelaic acid iontophoresis (AAI) versus
      topical treatment with azelaic acid cream in female patients with melasma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized and allocated in concealed manner to one of the two treatment
      arms: AAI or topical azelaic acid cream.

      Azelaic acid iontophoresis treatment schedule:

      Patients randomized to the AAI group will receive iontophoresis with 15% azelaic acid twice
      weekly over a period of 12 weeks.

      Azelaic acid topical treatment schedule:

      Patients randomized to the topical treatment group will receive topical treatment with 20%
      azelaic acid cream twice daily over a period of 12 weeks.

      Besides emollients no additional specific treatments will be allowed during the study.

      The use of broad spectrum (UVA+UVB) sunscreen is recommended over the entire study period (9
      month).

      Follow-up period:

      After completion of the active study period (3 month in both treatment groups), maintenance
      and efficacy of both treatment schedules will be followed up quarterly over 6 month
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in colorimetric measurement of skin colour and MASI-Score after 12 weeks of treatment</measure>
    <time_frame>3 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physician Global Assessment, Patient Global Assessment, Overall Response Assessment</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Melasma</condition>
  <arm_group>
    <arm_group_label>Azelaic Acid Iontophoresis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Azelaic acid topical</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Iontophoresis</intervention_name>
    <description>iontophoresis with 15% azelaic acid gel twice weekly</description>
    <arm_group_label>Azelaic Acid Iontophoresis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Azelaic acid cream</intervention_name>
    <description>topical treatment with 20% azelaic acid cream twice daily</description>
    <arm_group_label>Azelaic acid topical</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Woman

          -  MASI - Score over 6

          -  Age: over 18 years

          -  Skin Type: III, IV, V

        Exclusion Criteria:

          -  Skin Type: I, II, VI

          -  Pregnant or lactating women

          -  Local therapy of intent-to-treat area within the last 6 month

          -  Patient with a pacemaker or metal implant

          -  Epileptic

          -  Mental incompetence to understand the protocol

          -  Known allergic reactions to one of used substances

          -  Serious encroachment on physical condition
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JB Schmidt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MUV</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oliver Schanab, MD</last_name>
    <role>Study Director</role>
    <affiliation>MUV</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oliver Schanab, MD</last_name>
    <phone>004340400</phone>
    <phone_ext>5441</phone_ext>
    <email>oliver.schanab@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University Vienna / Depatment of Dermatology</name>
      <address>
        <city>Vienna</city>
        <zip>1180</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Schanab, MD</last_name>
      <phone>004340400</phone>
      <phone_ext>5441</phone_ext>
      <email>oliver.schanab@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>JB Schmidt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oliver Schanab, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Pinkowicz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2009</study_first_submitted>
  <study_first_submitted_qc>February 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2009</study_first_posted>
  <last_update_submitted>July 14, 2010</last_update_submitted>
  <last_update_submitted_qc>July 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Schmidt.JB.MD</name_title>
    <organization>Department of Dermatology / MUV</organization>
  </responsible_party>
  <keyword>Azelaic Acid</keyword>
  <keyword>Iontophoresis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azelaic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

